Abstract

BackgroundThe incidence of Hodgkin lymphoma (HL) among HIV-infected individuals remains unchanged since the introduction of combination antiretroviral therapy (cART). Recent epidemiological data suggest that CD4 count decline over a year is associated with subsequent diagnosis of HL. In an era of economic austerity monitoring the efficacy of cART by CD4 counts may no longer be required where CD4 count>350 cells/µl and viral load is suppressed (<50 copies/ml).MethodsWe sought to establish among our HIV outpatient cohort whether a CD4 count decline prior to diagnosis of HL, whether any decline was greater than in patients without the diagnosis, and also whether other clinical or biochemical indices were reliably associated with the diagnosis.ResultsTwenty-nine patients with a diagnosis of HL were identified. Among 15 individuals on cART with viral load <50 copies/ml the change in CD4 over 12 months preceding diagnosis of HL was −82 cells/µl (95% CI −163 to −3; p = 0.04). Among 18 matched controls the mean change was +5 cells/µl, 95% CI −70 to 80, p = 0.89). The decline in CD4 over the previous 6–12 months was somewhat greater in cases than controls (mean difference in change −55 cells/µl, 95% CI −151 to 39; p = 0.25). In 26 (90%) patients B symptoms had been present for a median of three months (range one–12) before diagnosis of HL.ConclusionsThe CD4 count decline in the 12 months prior to diagnosis of Hodgkin lymphoma among HIV-infected individuals with VL<50 copies/ml on cART was not significantly different from that seen in other fully virologically suppressed individuals in receipt of cART and who did not develop HL. All those who developed HL had B symptoms and/or new palpable lymphadenopathy, suggesting that CD4 count monitoring if performed less frequently, or not at all, among those virologically suppressed individuals with CD4 counts >350 may not have delayed diagnosis.

Highlights

  • While the incidence of AIDS-defining malignancies such as Kaposi sarcoma and non-Hodgkin lymphoma has fallen since the introduction of highly active antiretroviral therapy (HAART) [1,2], the incidence of Hodgkin lymphoma has not decreased, and remains elevated in HIV infected individuals [3,4,5,6,7]

  • We reviewed the CD4 dynamics, HAART history and clinical features in virologically suppressed patients with HIV-associated Hodgkin lymphoma and among matched controls to assess whether a CD4 count decline in virologically suppressed patients was indicative of development of Hodgkin lymphoma, and to identify if such a decline, if present, was associated with any clinical or laboratory markers suggestive of Hodgkin lymphoma

  • Demographics and Presentation Between January1996 and May 2012 a histologically-confirmed diagnosis of Hodgkin lymphoma was made in 29 HIV-infected patients: 27 (93%) were male and six (21%) were Black African

Read more

Summary

Introduction

While the incidence of AIDS-defining malignancies such as Kaposi sarcoma and non-Hodgkin lymphoma has fallen since the introduction of highly active antiretroviral therapy (HAART) [1,2], the incidence of Hodgkin lymphoma has not decreased, and remains elevated in HIV infected individuals [3,4,5,6,7]. A transient CD4 decline to ,350 cells/mm among virologically suppressed patients is common [2,14] and, given the low incidence of Hodgkin lymphoma among HIV-infected patients in Northern Europe, it is possible that a transient decline in CD4 count may trigger clinicians to undertake unnecessary investigations and follow up. The incidence of Hodgkin lymphoma (HL) among HIV-infected individuals remains unchanged since the introduction of combination antiretroviral therapy (cART). In an era of economic austerity monitoring the efficacy of cART by CD4 counts may no longer be required where CD4 count.350 cells/ml and viral load is suppressed (,50 copies/ml)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call